Detailed Information on Publication Record

@article{60470,
   author = {Mráz, Marek},
   address = {Washington DC, USA},
   article_number = {20},
   booktitle = {Blood},
   doi = {http://dx.doi.org/10.1182/blood.2023022305},
   keywords = {chronic lymphocytic leukemia; CD20 messenger RNA; alternative splicing; malignant B cells; anti-CD20 therapies},
   language = {eng},
   location = {Washington DC, USA},
   pages = {1676-1678},
   publisher = {American Society of Hematology},
   title = {5′-UTR mRNA splicing determines CD20 levels},
   url = {https://ashpublications.org/blood/article/142/20/1676/498635/5-UTR-mRNA-splicing-determines-CD20-levels},
   year = {2023}
}

TY  - JFULL
ID  - 60470
AU  - Mráz, Marek
PY  - 2023
TI  - 5′-UTR mRNA splicing determines CD20 levels
VL  - 142
IS  - 20
PB  - American Society of Hematology
CY  - Washington DC, USA
KW  - chronic lymphocytic leukemia
KW  - CD20 messenger RNA
KW  - alternative splicing
KW  - malignant B cells
KW  - anti-CD20 therapies
UR  - https://ashpublications.org/blood/article/142/20/1676/498635/5-UTR-mRNA-splicing-determines-CD20-levels
N2  - In this issue of Blood, Ang et al(1) show that human CD20 messenger RNA (mRNA) undergoes alternative splicing to generate distinct 5' untranslated region (5'-UTR) variants, which determine the cell-surface CD20 levels in malignant B cells and the interpatient variability in the expression of this therapeutic target. These variants can also be used as an escape mechanism from anti-CD20 therapies.
ER  - 

MRÁZ, Marek. 5′-UTR mRNA splicing determines CD20 levels. In \textit{Blood}. Washington DC, USA: American Society of Hematology, 2023, p.~1676-1678. 142. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood.2023022305.